IL266181B2 - Compounds and methods for modulating interleukin-2-inducible t-cell kinase - Google Patents
Compounds and methods for modulating interleukin-2-inducible t-cell kinaseInfo
- Publication number
- IL266181B2 IL266181B2 IL266181A IL26618119A IL266181B2 IL 266181 B2 IL266181 B2 IL 266181B2 IL 266181 A IL266181 A IL 266181A IL 26618119 A IL26618119 A IL 26618119A IL 266181 B2 IL266181 B2 IL 266181B2
- Authority
- IL
- Israel
- Prior art keywords
- unsubstituted
- membered
- substituted
- independently
- nhc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417083P | 2016-11-03 | 2016-11-03 | |
| PCT/US2017/059871 WO2018089261A2 (en) | 2016-11-03 | 2017-11-03 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL266181A IL266181A (en) | 2019-06-30 |
| IL266181B1 IL266181B1 (en) | 2023-12-01 |
| IL266181B2 true IL266181B2 (en) | 2024-04-01 |
Family
ID=62109599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266181A IL266181B2 (en) | 2016-11-03 | 2017-11-03 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11008314B2 (enExample) |
| EP (1) | EP3534899B1 (enExample) |
| JP (2) | JP7236996B2 (enExample) |
| KR (1) | KR102540515B1 (enExample) |
| CN (1) | CN110099684B (enExample) |
| AU (1) | AU2017358901B2 (enExample) |
| CA (2) | CA3278142A1 (enExample) |
| DK (1) | DK3534899T3 (enExample) |
| ES (1) | ES2926153T3 (enExample) |
| IL (1) | IL266181B2 (enExample) |
| MX (1) | MX392031B (enExample) |
| PT (1) | PT3534899T (enExample) |
| WO (1) | WO2018089261A2 (enExample) |
| ZA (1) | ZA201903071B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| PT3534899T (pt) * | 2016-11-03 | 2022-07-07 | Corvus Pharmaceuticals Inc | Compostos e métodos de modulação da cinase de células t induzível por interleucina-2 |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| AU2019364417A1 (en) * | 2018-10-24 | 2021-05-20 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis |
| US20230029266A1 (en) * | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2021297778A1 (en) | 2020-06-23 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use |
| CN114605404B (zh) * | 2022-03-23 | 2024-01-05 | 合肥美诺医药有限公司 | 一种新型含噻唑类化合物、中间体及其应用 |
| CN114621213B (zh) * | 2022-03-23 | 2023-12-08 | 合肥美诺医药有限公司 | 含噻唑类化合物及其中间体与应用 |
| KR20240169633A (ko) * | 2022-04-05 | 2024-12-03 | 코버스 파마슈티칼스, 인크. | Th1 세포 활성을 증가시키기 위한 itk 저해제 |
| WO2025085889A1 (en) * | 2023-10-20 | 2025-04-24 | Corvus Pharmaceuticals, Inc. | Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses |
| WO2025171035A1 (en) * | 2024-02-06 | 2025-08-14 | Corvus Pharmaceuticals, Inc. | Itk inhibitors and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706717B2 (en) * | 2000-12-21 | 2004-03-16 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
| US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0212101A (pt) * | 2001-08-24 | 2004-08-24 | Pharmacia & Up John Company | 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças |
| US7973169B2 (en) * | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US8222285B2 (en) | 2007-06-11 | 2012-07-17 | Bristol-Myers Squibb Company | 1,3-dihydroxy substituted phenylamide glucokinase activators |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| US9649313B2 (en) | 2012-11-26 | 2017-05-16 | The University Of North Carolina At Chapel Hill | Use of ITK inhibitors for the treatment of cancer |
| CN105164112B (zh) | 2013-01-31 | 2017-10-13 | 中国科学院上海药物研究所 | 酰胺类化合物及其制备方法、药物组合物和用途 |
| CA2965178C (en) | 2014-10-22 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| EP3197836A1 (en) * | 2014-11-19 | 2017-08-02 | Hach Lange GmbH | Control of wastewater treatment based on regulatory period |
| CN105884711A (zh) | 2014-12-16 | 2016-08-24 | 中国药科大学 | 噻唑类化合物、其制备方法及其在制药中的用途 |
| WO2017044858A2 (en) * | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| PT3534899T (pt) * | 2016-11-03 | 2022-07-07 | Corvus Pharmaceuticals Inc | Compostos e métodos de modulação da cinase de células t induzível por interleucina-2 |
-
2017
- 2017-11-03 PT PT178687299T patent/PT3534899T/pt unknown
- 2017-11-03 KR KR1020197015471A patent/KR102540515B1/ko active Active
- 2017-11-03 WO PCT/US2017/059871 patent/WO2018089261A2/en not_active Ceased
- 2017-11-03 US US16/346,360 patent/US11008314B2/en active Active
- 2017-11-03 DK DK17868729.9T patent/DK3534899T3/da active
- 2017-11-03 CA CA3278142A patent/CA3278142A1/en active Pending
- 2017-11-03 EP EP17868729.9A patent/EP3534899B1/en active Active
- 2017-11-03 CN CN201780079068.5A patent/CN110099684B/zh active Active
- 2017-11-03 ES ES17868729T patent/ES2926153T3/es active Active
- 2017-11-03 CA CA3042252A patent/CA3042252C/en active Active
- 2017-11-03 IL IL266181A patent/IL266181B2/en unknown
- 2017-11-03 MX MX2019005076A patent/MX392031B/es unknown
- 2017-11-03 JP JP2019522993A patent/JP7236996B2/ja active Active
- 2017-11-03 AU AU2017358901A patent/AU2017358901B2/en active Active
-
2019
- 2019-05-16 ZA ZA2019/03071A patent/ZA201903071B/en unknown
-
2021
- 2021-04-07 US US17/224,410 patent/US11897874B2/en active Active
-
2022
- 2022-11-18 JP JP2022184820A patent/JP2023029752A/ja active Pending
-
2024
- 2024-02-12 US US18/439,695 patent/US12686677B2/en active Active
-
2026
- 2026-03-17 US US19/569,194 patent/US20260209216A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706717B2 (en) * | 2000-12-21 | 2004-03-16 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
| US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240383884A1 (en) | 2024-11-21 |
| KR102540515B1 (ko) | 2023-06-05 |
| CN110099684A (zh) | 2019-08-06 |
| US11008314B2 (en) | 2021-05-18 |
| CA3042252C (en) | 2025-10-21 |
| DK3534899T3 (da) | 2022-06-20 |
| AU2017358901B2 (en) | 2023-01-05 |
| CA3278142A1 (en) | 2025-10-31 |
| US20220363676A1 (en) | 2022-11-17 |
| JP2023029752A (ja) | 2023-03-06 |
| EP3534899B1 (en) | 2022-06-01 |
| WO2018089261A2 (en) | 2018-05-17 |
| WO2018089261A3 (en) | 2018-08-02 |
| JP2019536763A (ja) | 2019-12-19 |
| JP7236996B2 (ja) | 2023-03-10 |
| EP3534899A2 (en) | 2019-09-11 |
| MX392031B (es) | 2025-03-21 |
| US20260209216A1 (en) | 2026-07-23 |
| PT3534899T (pt) | 2022-07-07 |
| CA3042252A1 (en) | 2018-05-17 |
| IL266181B1 (en) | 2023-12-01 |
| MX2019005076A (es) | 2019-11-12 |
| AU2017358901A1 (en) | 2019-05-30 |
| EP3534899A4 (en) | 2020-04-29 |
| US11897874B2 (en) | 2024-02-13 |
| ES2926153T3 (es) | 2022-10-24 |
| CN110099684B (zh) | 2022-11-11 |
| IL266181A (en) | 2019-06-30 |
| US12686677B2 (en) | 2026-07-21 |
| KR20190089891A (ko) | 2019-07-31 |
| US20190375743A1 (en) | 2019-12-12 |
| ZA201903071B (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266181B1 (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
| EP3426637B1 (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
| CA3168494A1 (en) | Pgdh inhibitors and methods of making and using | |
| KR20230092958A (ko) | Mas-관련 G-단백질 수용체 X2의 조절제 및 관련 생성물 및 이의 용도 | |
| AU2016325601B2 (en) | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | |
| CA3021324A1 (en) | Erbb inhibitors and uses thereof | |
| CA3017567C (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
| US20210115066A1 (en) | Dithio etp derivatives | |
| US20200079793A1 (en) | Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor | |
| HK40014009A (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
| HK40014009B (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
| CA3019130C (en) | Inhibitors of integrin alpha 5 beta 1 and methods of use | |
| HK40016226A (en) | Compounds for modulating adenosine a2b receptor and adenosine a2a receptor | |
| WO2024019995A1 (en) | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof | |
| CA3205106A1 (en) | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders | |
| CA3019130A1 (en) | Inhibitors of integrin alpha 5 beta 1 and methods of use |